Our top pick for
Artelo Biosciences, Inc is a biotechnology business based in the US. Artelo Biosciences shares (ARTL) are listed on the NASDAQ and all prices are listed in US Dollars. Artelo Biosciences employs 3 staff and has a market cap (total outstanding shares value) of USD$9.7 million.
|Latest market close||USD$1.02|
|52-week range||USD$0.451 - USD$3.08|
|50-day moving average||USD$0.5962|
|200-day moving average||USD$0.9019|
|Wall St. target price||USD$8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.082|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||2.00%|
|1 month (2020-12-15)||55.25%|
|3 months (2020-10-15)||56.20%|
|6 months (2020-07-15)||-5.56%|
|1 year (2020-01-15)||-56.13%|
|2 years (2019-01-15)||-11.30%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-53.94%|
|Return on equity TTM||-99.72%|
|Market capitalisation||USD$9.7 million|
TTM: trailing 12 months
There are currently 592,848 Artelo Biosciences shares held short by investors – that's known as Artelo Biosciences's "short interest". This figure is 3.1% up from 575,184 last month.
There are a few different ways that this level of interest in shorting Artelo Biosciences shares can be evaluated.
Artelo Biosciences's "short interest ratio" (SIR) is the quantity of Artelo Biosciences shares currently shorted divided by the average quantity of Artelo Biosciences shares traded daily (recently around 3.1 million). Artelo Biosciences's SIR currently stands at 0.19. In other words for every 100,000 Artelo Biosciences shares traded daily on the market, roughly 190 shares are currently held short.
However Artelo Biosciences's short interest can also be evaluated against the total number of Artelo Biosciences shares, or, against the total number of tradable Artelo Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Artelo Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Artelo Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0402% of the tradable shares (for every 100,000 tradable Artelo Biosciences shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Artelo Biosciences.
Find out more about how you can short Artelo Biosciences stock.
We're not expecting Artelo Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Artelo Biosciences's shares have ranged in value from as little as $0.451 up to $3.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Artelo Biosciences's is 1.422. This would suggest that Artelo Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.